Irbesartan is projected to be cost and life saving compared to standard blood pressure control alone fortreatment of patients with type 2 diabetes, hypertension, and microalbuminuria in Spanish, Swedish and Swiss settings

被引：1

作者：

Palmer, AJ

Roze, S

Valentine, WJ

Annemans, L

Gabriel, S

Chen, R

机构：

[1] CORE, Ctr Outcomes Res, Basel, Switzerland

[2] HEDM, Meise, Belgium

[3] Sanofi Synthelabo, Bagneux, France

[4] Bristol Myers Squibb, Princeton, NJ 08543 USA

来源：

关键词：

D O I：

10.1016/S1098-3015(10)65692-6

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：655 / 655

页数：1